Does the media prefer AVBP or XFOR?

In the previous week, ArriVent BioPharma had 3 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for ArriVent BioPharma and 1 mentions for X4 Pharmaceuticals. ArriVent BioPharma's average media sentiment score of 1.08 beat X4 Pharmaceuticals' score of 0.67 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ABSI or XFOR?

X4 Pharmaceuticals has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Absci $2.80M 596.96 -$115.18M -$0.80 N/A X4 Pharmaceuticals $35.11M 8.78 -$79.20M -$1.20 N/A

Is ABSI or XFOR more profitable?

X4 Pharmaceuticals has a net margin of -568.80% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat X4 Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Absci -7,756.38% -61.71% -54.52% X4 Pharmaceuticals -568.80% -63.05% -36.89%

Does the media favor ABSI or XFOR?

In the previous week, Absci had 4 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 5 mentions for Absci and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.67 beat Absci's score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral X4 Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XFOR or MAZE?

In the previous week, Maze Therapeutics had 7 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 8 mentions for Maze Therapeutics and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.67 beat Maze Therapeutics' score of 0.36 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, XFOR or VOR?

Vor Biopharma has lower revenue, but higher earnings than X4 Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio X4 Pharmaceuticals $35.11M 8.78 -$79.20M -$1.20 N/A Vor Biopharma N/A N/A N/A N/A N/A

Does the media favor XFOR or VOR?

In the previous week, Vor Biopharma had 7 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 8 mentions for Vor Biopharma and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.67 beat Vor Biopharma's score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to XFOR or RARE?

In the previous week, Ultragenyx Pharmaceutical had 36 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 37 mentions for Ultragenyx Pharmaceutical and 1 mentions for X4 Pharmaceuticals. Ultragenyx Pharmaceutical's average media sentiment score of 0.70 beat X4 Pharmaceuticals' score of 0.67 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 12 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

X4 Pharmaceuticals (XFOR) Competitors

$3.11 -0.32 (-9.33%)

Closing price 04:00 PM Eastern

Extended Trading

$3.14 +0.03 (+0.93%)

As of 07:54 PM Eastern

Compare

XFOR vs. AVBP, ABSI, MAZE, VOR, and RARE

Should you buy X4 Pharmaceuticals stock or one of its competitors? X4 Pharmaceuticals's main competitors and comparable companies include ArriVent BioPharma (AVBP), Absci (ABSI), Maze Therapeutics (MAZE), Vor Biopharma (VOR), and Ultragenyx Pharmaceutical (RARE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does X4 Pharmaceuticals compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

ArriVent BioPharma has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

In the previous week, ArriVent BioPharma had 3 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for ArriVent BioPharma and 1 mentions for X4 Pharmaceuticals. ArriVent BioPharma's average media sentiment score of 1.08 beat X4 Pharmaceuticals' score of 0.67 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ArriVent BioPharma has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. ArriVent BioPharma's return on equity of -50.26% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%

X4 Pharmaceuticals has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
X4 Pharmaceuticals	$35.11M	8.78	-$79.20M	-$1.20	N/A

ArriVent BioPharma presently has a consensus price target of $44.86, indicating a potential upside of 48.04%. X4 Pharmaceuticals has a consensus price target of $11.25, indicating a potential upside of 261.74%. Given X4 Pharmaceuticals' higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ArriVent BioPharma beats X4 Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Absci?

Absci (NASDAQ:ABSI) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

52.1% of Absci shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 10.5% of Absci shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Absci had 4 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 5 mentions for Absci and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.67 beat Absci's score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Absci currently has a consensus target price of $13.71, suggesting a potential upside of 40.80%. X4 Pharmaceuticals has a consensus target price of $11.25, suggesting a potential upside of 261.74%. Given X4 Pharmaceuticals' higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

X4 Pharmaceuticals has a net margin of -568.80% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%

Absci has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

X4 Pharmaceuticals has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	596.96	-$115.18M	-$0.80	N/A
X4 Pharmaceuticals	$35.11M	8.78	-$79.20M	-$1.20	N/A

Summary

Absci and X4 Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Maze Therapeutics?

X4 Pharmaceuticals (NASDAQ:XFOR) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

72.0% of X4 Pharmaceuticals shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Maze Therapeutics had 7 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 8 mentions for Maze Therapeutics and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.67 beat Maze Therapeutics' score of 0.36 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

X4 Pharmaceuticals has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	8.78	-$79.20M	-$1.20	N/A
Maze Therapeutics	$167.50M	9.32	-$131.12M	-$2.52	N/A

X4 Pharmaceuticals presently has a consensus target price of $11.25, suggesting a potential upside of 261.74%. Maze Therapeutics has a consensus target price of $63.40, suggesting a potential upside of 125.70%. Given X4 Pharmaceuticals' higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Maze Therapeutics has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. Maze Therapeutics' return on equity of -34.94% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
Maze Therapeutics	N/A	-34.94%	-30.18%

X4 Pharmaceuticals has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market.

Summary

Maze Therapeutics beats X4 Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Vor Biopharma?

X4 Pharmaceuticals (NASDAQ:XFOR) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Vor Biopharma has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. Vor Biopharma's return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
Vor Biopharma	N/A	N/A	N/A

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Vor Biopharma has lower revenue, but higher earnings than X4 Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	8.78	-$79.20M	-$1.20	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

X4 Pharmaceuticals has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

X4 Pharmaceuticals presently has a consensus target price of $11.25, indicating a potential upside of 261.74%. Vor Biopharma has a consensus target price of $43.38, indicating a potential upside of 123.93%. Given X4 Pharmaceuticals' higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Vor Biopharma had 7 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 8 mentions for Vor Biopharma and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.67 beat Vor Biopharma's score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vor Biopharma beats X4 Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Ultragenyx Pharmaceutical?

X4 Pharmaceuticals (NASDAQ:XFOR) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

X4 Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

X4 Pharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	8.78	-$79.20M	-$1.20	N/A
Ultragenyx Pharmaceutical	$673M	2.18	-$575M	-$5.84	N/A

In the previous week, Ultragenyx Pharmaceutical had 36 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 37 mentions for Ultragenyx Pharmaceutical and 1 mentions for X4 Pharmaceuticals. Ultragenyx Pharmaceutical's average media sentiment score of 0.70 beat X4 Pharmaceuticals' score of 0.67 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	12 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

X4 Pharmaceuticals presently has a consensus target price of $11.25, indicating a potential upside of 261.74%. Ultragenyx Pharmaceutical has a consensus target price of $34.58, indicating a potential upside of 132.39%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe X4 Pharmaceuticals is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48

Ultragenyx Pharmaceutical has a net margin of -81.79% compared to X4 Pharmaceuticals' net margin of -568.80%. X4 Pharmaceuticals' return on equity of -63.05% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Ultragenyx Pharmaceutical beats X4 Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get X4 Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XFOR vs. The Competition

Export

Metric	X4 Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$340.07M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-2.59	7.95	209.51	20.92
Price / Sales	8.78	1,367.44	649.76	88.01
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.46	15.30	10.44	6.32
Net Income	-$79.20M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-11.40%	-0.22%	0.51%	1.35%
1 Month Performance	-23.02%	-6.06%	-3.38%	-3.68%
1 Year Performance	-9.86%	34.37%	16.04%	5.56%

X4 Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XFOR X4 Pharmaceuticals	1.8279 of 5 stars	$3.11 -9.3%	$11.25 +261.7%	+1.5%	$340.07M	$35.11M	N/A	45	High Trading Volume
AVBP ArriVent BioPharma	2.5672 of 5 stars	$28.17 -1.4%	$44.86 +59.2%	+62.8%	$1.38B	N/A	N/A	77	Positive News Analyst Forecast
ABSI Absci	2.3111 of 5 stars	$7.87 -2.7%	$13.71 +74.3%	+298.1%	$1.36B	$1.56M	N/A	140	News Coverage Analyst Forecast
MAZE Maze Therapeutics	2.8451 of 5 stars	$24.19 -2.0%	$66.00 +172.9%	+19.9%	$1.34B	$20M	N/A	141	Positive News Analyst Forecast
VOR Vor Biopharma	1.3455 of 5 stars	$22.73 -1.5%	$43.38 +90.8%	-21.2%	$1.34B	N/A	N/A	76	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XFOR) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. AVBP, ABSI, MAZE, VOR, and RARE

How does X4 Pharmaceuticals compare to ArriVent BioPharma?

Summary

How does X4 Pharmaceuticals compare to Absci?

Summary

How does X4 Pharmaceuticals compare to Maze Therapeutics?

Summary

How does X4 Pharmaceuticals compare to Vor Biopharma?

Summary

How does X4 Pharmaceuticals compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. AVBP, ABSI, MAZE, VOR, and RARE

How does X4 Pharmaceuticals compare to ArriVent BioPharma?

Which has more volatility & risk, AVBP or XFOR?

Does the media prefer AVBP or XFOR?

Is AVBP or XFOR more profitable?

Which has better earnings & valuation, AVBP or XFOR?

Do analysts rate AVBP or XFOR?

Do insiders and institutionals believe in AVBP or XFOR?

Summary

How does X4 Pharmaceuticals compare to Absci?

Do insiders and institutionals hold more shares of ABSI or XFOR?

Does the media favor ABSI or XFOR?

Do analysts rate ABSI or XFOR?

Is ABSI or XFOR more profitable?

Which has more volatility & risk, ABSI or XFOR?

Which has stronger valuation & earnings, ABSI or XFOR?

Summary

How does X4 Pharmaceuticals compare to Maze Therapeutics?

Do institutionals and insiders believe in XFOR or MAZE?

Does the media refer more to XFOR or MAZE?

Which has preferable valuation & earnings, XFOR or MAZE?

Do analysts prefer XFOR or MAZE?

Is XFOR or MAZE more profitable?

Which has more volatility & risk, XFOR or MAZE?

Summary

How does X4 Pharmaceuticals compare to Vor Biopharma?

Is XFOR or VOR more profitable?

Do institutionals & insiders have more ownership in XFOR or VOR?

Which has stronger valuation and earnings, XFOR or VOR?

Which has more risk and volatility, XFOR or VOR?

Do analysts recommend XFOR or VOR?

Does the media favor XFOR or VOR?

Summary

How does X4 Pharmaceuticals compare to Ultragenyx Pharmaceutical?

Which has more risk & volatility, XFOR or RARE?

Which has higher valuation & earnings, XFOR or RARE?

Does the media refer more to XFOR or RARE?

Do analysts recommend XFOR or RARE?

Is XFOR or RARE more profitable?

Do institutionals & insiders have more ownership in XFOR or RARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools